All News
🔎Look! Urinary biomarkers vs. UPCR in tx response of #lupus nephritis by Dr @andreafava et al
🦋A decline in several urinary BMs at 3 mos outperformed UPCR in predicting the 1 yr response.
Urinary BMs as surrogate endpts in trials?🤔#ACR22 @RheumNow ABST0536 https://t.co/kMWmsK8mnO
sheila RHEUMarampa ( View Tweet)
@GuyKatzMD @zach_wallace_md et al. Hypocomplementemia seen in 30% IgG4-RD. More organs involved (mean 4.3 vs 2.9). More likely to have serum IgG4 above ULN (89%vs74%) and 5XULN (52%vs28%) @rheumnow #ACR22 Abstr#0144 https://t.co/bVRTuh3dsU https://t.co/3SHEbg2tbR
Richard Conway RichardPAConway ( View Tweet)
Sanchez-Bilbao et al. IV vs SC tocilizumab in 471 GCA patients. No differences in sustained remission or glucocorticoid-sparing. Numerically more AEs in IV but this due to longer follow up, no difference when corrected @rheumnow #ACR22 Abstr#0146 https://t.co/EB2RMYdzAr https://t.co/4xIMH1PIt3
Richard Conway RichardPAConway ( View Tweet)
Fussner @LynnFussner et al. DAH in PEXIVAS. DAH more freq younger, PR3+, relapsing, higher disease activity, higher creatinine. DAH more likely to die at 30 days and 1 year than those without DAH @RheumNow #ACR22 Abstr#0526 https://t.co/XGYHvDkVeA https://t.co/IEOcQHEQ3e
Richard Conway RichardPAConway ( View Tweet)
Normal weight PsA pts had numerically better PsAID and PGA scores than obese PsA pts when treated with SEC. SEC was effective in all BMI subgroups. Abs 0395 #ACR22 @RheumNow https://t.co/oBSsuJKRem https://t.co/BhybOk76Gr
Dr. Rachel Tate uptoTate ( View Tweet)
Werth et al. Lenabasum phase 3 trial indermatomyositis. Primary endpoint (TIS week 28) not met. Subgroup analysis suggest small effect on muscle and modest effect on skin disease @rheumnow #ACR22 Abstr#0173 https://t.co/qhL2PcTcHV https://t.co/uR8Bg5awiK
Richard Conway RichardPAConway ( View Tweet)
Vikse et al. Norwegian case series of 40 patients treated with RTX for IgG4-RD. Efficacy across phenotypes 80-100% for improvement but only 45-78% for remission. @rheumnow #ACR22 Abstr#0147 https://t.co/J7b47ywbt0 https://t.co/pfhOIG5qXk
Richard Conway RichardPAConway ( View Tweet)
This work can lay foundation to so much more!
#ArtificialIntelligence and #naturallanguageprocessing on Facebook private #gout groups
- Mental health mentioned in 4% of all posts/comments
- primary care asso with “trust” and urgent care with “fear”
@RheumNow #ACR22 abst#0201 https://t.co/fSuOeNGWvg
Bella Mehta bella_mehta ( View Tweet)
Liew @rheum_cat et al. No evidence of cardioprotective effect of early initiation of TNFi in AxSpA. In fact seemed to be associated higher risk! CVD (HR 1.17), stroke (HR 1.24), and MACE (HR 1.22) @rheumnow #ACR22 Abstr#0415 https://t.co/a9lpxQuMB9 https://t.co/GdGfYxcAH6
Richard Conway RichardPAConway ( View Tweet)
Germano et al. Physical exam of temporal arteries predictive of TAB+. Decreased pulse nad thickened artery most useful @rheumnow #ACR22 Abstr#0483 https://t.co/NGvu8pMiaj https://t.co/F0Y9oy0hWy
Richard Conway RichardPAConway ( View Tweet)
Merkel. Vilobelimab in AAV. C5a mab. Phase 2. Given with RTX/CYC. Various steroid regimes (none, reduced, standard). Not powered for non-inferiority but encouraging results. Makes sense, this is the same pathway as avacopan @RheumNow #ACR22 Abstr#0524 https://t.co/HY5i6wqnjI https://t.co/CTXUdP3PZV
Richard Conway RichardPAConway ( View Tweet)
Exciting development in Lupus!
Change in urinary biomarkers (CD163 and MMR) better predictor than proteinuria for lupus nephritis treatment response.
Larger longitudinal studies needed.
Abs#0536
@RheumNow #ACR22
#ACRBest https://t.co/MLSWdl0xUo
Robert B Chao, MD doctorRBC ( View Tweet)
Bandeira et al. When to look for cardiac involvement in IIM. Lung involvement and anti-SRP abs both ORs of >7 main warning signs @rheumnow #ACR22 Abstr#0171 https://t.co/02cKN23Ufq https://t.co/3NioXUwVPM
Richard Conway RichardPAConway ( View Tweet)
Pearl - ‘Three Useful Ophthalmologic Acronyms’ with Dr. John Stone
KP- Keratic Precipitates
PUK- Peripheral Ulcerative Keratitis
IOI- Idiopathic Orbital Inflammation
Add PUK to the Rheum Emergencies. Seen in #RA and #AAV
@RheumNow #ACR22 https://t.co/GUc9boY0WV
Akhil Sood MD AkhilSoodMD ( View Tweet)
Yang et al. Incidence and risk factors for cutaneous lupus becoming SLE. 11.8% transitioned after 20 years. Age<40 (HR 3.25), in first 10 years after skin lupus diagnosis, SCLE>DLE (HR 0.28)/others (HR 0.11) @rheumnow #ACR22 Abstr#0338 https://t.co/IxVS4mOveD https://t.co/3VeQ8WPQtU
Richard Conway RichardPAConway ( View Tweet)
Clinical pearl! Talk to your PsA pts about sleep. Abs 0387 shows circular relationship between sleep quality, emotional disorders, and activity in these patients. Emotional factors more relevant than inflammatory factors on sleep quality. #ACR22 @RheumNow https://t.co/0p5hfNHM91 https://t.co/XrMTmsoMYR
Dr. Rachel Tate uptoTate ( View Tweet)
Patel @NaomiRheumMD et al. Baseline GTI in GCA in GiACTA. Blood pressure and glucose tolerance biggest contributors. Higher in relapsing 122.5 vs 98.9. BMI and neuropsych higher in relapsing. @rheumnow #ACR22 Abstr#0460 https://t.co/dSIt1xEOva https://t.co/2tAkgVEEeA
Richard Conway RichardPAConway ( View Tweet)
Patel @NaomiRheumMD et al. HbA1c in GiACTA. Tocilizumab assoc HbA1c reduction independent of steroids. Daily steroid dose assoc HbA1c @rheumnow #ACR22 Abstr#0461 https://t.co/9Nbewrpww8 https://t.co/NyeTyWICF6
Richard Conway RichardPAConway ( View Tweet)
Clinical pearl! Patient-reported treatment success in PsA assoc'd w/ control of arthritis, dactylitis, psoriasis, and health-related QoL. Top 3 pt-reported reasons for tx failure were pain, psoriasis and fatigue. Abs0393 #ACR22 @RheumNow https://t.co/F9RNI7EXcL https://t.co/7DcLaqUqnm
Dr. Rachel Tate uptoTate ( View Tweet)
Smith et al. MMF equally good if not better for Black vs White patients with SSc-ILD. Suggests worse outcomes for Black patients relate to more severe disease at presentation rather than treatment failure @RheumNow #ACR22 Abstr#0521 https://t.co/xZtAt6Kw1f https://t.co/f0jG9jsgQ7
Richard Conway RichardPAConway ( View Tweet)